YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) in South Korea for a Phase 1...
Hence then, the article about gc biopharma submits ind application for phase 1 clinical trial of covid 19 mrna vaccine in korea was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea )
Also on site :
- Skier dies in collision with tree at Colorado’s Aspen Mountain, resort officials confirm
- Tornado warning issued, and quickly cancelled, over Alhambra
- Governor Hochul: Annual statewide donation drive is complete